# A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

> **NCT07195682** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 125 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** BMS-986506

## Key facts

- **NCT ID:** NCT07195682
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2030-05-03
- **Final completion:** 2031-04-03
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07195682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07195682, "A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07195682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*